FINDING COMMON INVOLUTION BETWEEN TYPE 2 DIABETES AND ALZHEIMER’S DISEASE (TYPE 3 DIABETES) AND THE RECENT ADVANCEMENT IN THEIR THERAPEUTIC REGIME USING COMPUTATIONAL APPROACH

Abstract

More than 44 million people worldwide suffer with Alzheimer's disease (AD), a neurodegenerative condition which shows amyloid peptide accumulation, development of neuro-fibrillary tangles, and tau proteins hyperphosphorylation. Several variables, including insulin resistance, hyperglycaemia, protein misfolding, and altered equilibrium between amyloid peptide integration and disintegration, are to blame for the beginning of AD and the course of the disease. The effectiveness and serious complexity of the therapeutic techniques now utilised to treat disease have a variety of constraints. Therefore, the need for a superior therapeutic agent that can meet the demand for AD treatment is crucial in the current environment. The current project focuses on therapeutic approaches that are both now in use and being developed to treat AD and other neurodegenerative diseases. To paint a clear picture of the important therapeutic candidates for the AD treatment, the study addressed in detail all the available plant-based secondary metabolites and FDA-approved medication candidates. In this project we have used computational approach for the study of various pharmacokinetic properties of potential therapeutic agents wherein we have performed molecular docking of various therapeutic candidates with respective target molecules to evaluate their binding energy. Further, we have performed thorough analysis of these therapeutic agents for their suitable pharmacokinetic characteristics using SWISS ADME online server tool. At last, we have discussed about the development of combinatorial and synergistic drug formulation and multi-target-domain-ligand (MTDL) drug formulation that are the recent developments in the therapeutic strategy .